ReS 39
Alternative Names: ReS-39Latest Information Update: 28 Dec 2022
At a glance
- Originator reMYND
- Class Antihyperglycaemics; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Parkinson's disease
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in Belgium
- 28 Dec 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in Belgium
- 21 Jan 2021 reMYND plans a first-in-human clinical trial for Diabetes mellitus, in 2021